Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.


CSE:PHRX - Post by User

Comment by Blahblahblahblaon Apr 09, 2022 4:36pm
82 Views
Post# 34591062

RE:PharmaDrug Advances DMT-Analogue Program for Glaucoma

RE:PharmaDrug Advances DMT-Analogue Program for Glaucoma Exciting times for shareholders. Everything moving forward and into place nicely.
<< Previous
Bullboard Posts
Next >>